David Li

David Li is the CEO and co-founder of Meliora Therapeutics, a biotech working to develop life-saving cancer therapies using cutting-edge science and machine learning. Meliora derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques. 

Before founding Meliora, David served as Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and was head of commercial operations at Benchling, a life sciences software platform company which has achieved a $6 billion valuation and has attracted over $500 million in funding from firms such as Altimeter Capital, Tiger Global, Lone Pine Capital, Benchmark, Sequoia, Excel, Lux, and numerous others.

David began his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, where he advised and invested in transactions worth over $10 billion in enterprise value.

David's multifaceted experiences in the financial and life science sectors give him a wide range of experiences that founders can learn from.